fda2outsideweb

FDA approves Dechra’s generic antibiotic

pharmafile | September 9, 2016 | News story | Medical Communications, Sales and Marketing Dechra, Putney, antiobiotic, generic 

Dechra has announced that the US Food and Drug Administration (FDA) has approved its generic antibiotic. The product will be first generic drug to enter the sizeable antibiotic market, according to the company.

The approval is doubly significant for the company as it is the first they have achieved through recently-acquired US-based business Putney.  

Dechra’s CEO Ian Page commented: “We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra’s position in the US market.”

Advertisement

Matt Fellows

Related Content

glenmark

FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis

Glenmark Pharma will be celebrating after it secured FDA approval in the US to market …

biogen-idec-tecfidera-dimethyl-fumarate

Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …

mylan_building

Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India

Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for …

The Gateway to Local Adoption Series

Latest content